RAET1L and neoplasm: This delayed difference in tumor growth inhibition between the two treatment arms could be attributed to the inherently slow growth of the PDX model, delayed accumulation of soluble and/or membrane-associated ULBP6/2/5, and/or delayed NK cell proliferation in the 23ME-01473 treatment arm.